#China #Hangzhou #Investor Day #medical technology #Zylox-Tonbridge

Zylox-Tonbridge Hosts Investor Open Day

On January 11, 2026, Zylox-Tonbridge Medical Technology Co., Ltd., listed on the Hong Kong Stock Exchange (HKEX: 2190), held its Investor Open Day at the Zhuhai Innovation Center. The event welcomed nearly 150 institutional investors and sell-side analysts, providing a platform for the company to showcase its impressive innovation pipeline and global growth strategy.

The highlight of the event was Zylox-Tonbridge's commitment to establishing a competitive presence in vascular intervention. The company aims to achieve this through a combination of research-driven innovations, a robust global manufacturing platform, and an extensive international footprint. Attendees gained valuable insights from management presentations, product demonstrations, and facility tours, helping them understand how the company’s innovation engine is aligned with its long-term growth objectives.

Pioneering Products in Vascular Intervention

During the event, Zylox-Tonbridge presented an array of commercialized products, particularly underlining their late-stage pipeline in neurovascular and peripheral vascular interventions. Noteworthy among these innovations were the following:

• - ZYLOX Mammoth™ Large-Bore Thrombectomy Catheter: This unique catheter is China's only 12F–18F device designed for peripheral thrombectomy, featuring a proprietary flared tip that optimizes clot removal efficiency, particularly for deep vein thrombosis (DVT).

• - Feilong™ Embolization Assist Stent: Recognized as the first of its kind in China utilizing Drawn Filled Tubing (DFT) braided technology, this stent offers full-length radiopacity, enhancing both procedural precision and clinical confidence.

Furthermore, Zylox-Tonbridge introduced its image-guided therapy platform, which includes the intravascular optical coherence tomography (OCT) system and the ZYLOX Pantheris™ atherectomy catheter. This revolutionary solution, the only one of its kind commercially available, enables real-time visualization during plaque removal in peripheral arteries, marking a significant evolution towards precision-based, image-guided intervention standards in global medical practice.

Strategic Conversations on Growth

Throughout the day, the company’s leadership emphasized their dual engines of growth: innovation and globalization. Dr. Jonathon Zhong Zhao, Chairman and CEO, elaborated, "Our objective at Zylox-Tonbridge is to craft a globally competitive vascular intervention platform. By fusing clinically significant innovation with scalable manufacturing and a rapidly growing international distribution network, we are poised for sustainable global growth."

The company reported that by 2025, its products had been used in over one million procedures, reflecting strong adoption rates among healthcare practitioners. Zylox-Tonbridge has also accelerated its global outreach, achieving commercial coverage in 83 countries and regions while forming strategic alliances with over 80 distributors and partners worldwide. The dedicated focus remains on strengthening the operational foundations—regulatory, manufacturing, quality systems, and marketing execution—to facilitate continued organic growth and targeted external expansions in major global medtech markets.

About Zylox-Tonbridge

Zylox-Tonbridge Medical Technology Co., Ltd. is a pioneering medical technology firm specializing in the innovative research, development, and manufacturing of medical devices within the vascular intervention realm. Established in 2012 and headquartered in Hangzhou, China, the company boasts integrated capabilities spanning in-house R&D, manufacturing, and commercialization. Zylox-Tonbridge is committed to its philosophy of "Innovation for Quality Life," striving to deliver high-quality and affordable medical devices that enhance patient outcomes through advanced medical technologies.

For more insights, visit their official website.